Abstract
Various anticancer agents-incorporating polymeric micelles, categorized as passive targeting nanoparticles are currently under clinical evaluation. On the other hand, recently, several polymeric micelles with the active targeting ability using tumor-specific antibody have been developed and exhibited the potent antitumor activity in the preclinical studies. We introduce the characteristics and developmental status of these immunoconjugates.